Search research articles
Contact Us
Filters
Showing results (91-100 of 154) with videos related to
Page
of 16
Sort By:
Leukemia
|
August 30, 2017
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
R Chakraborty, E Muchtar, S K Kumar, et al.
Bone Marrow Transplantation
|
October 12, 2010
Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention
S Sinha, D Gastineau, I Micallef, et al.
Blood
|
September 25, 2001
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis
S R Hayman, R J Bailey, S M Jalal, et al.
Bone Marrow Transplantation
|
November 26, 2013
Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation
C O Freytes, D H Vesole, J LeRademacher, et al.
Bone Marrow Transplantation
|
September 4, 2003
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
I M Ghobrial, A Dispenzieri, K L Bundy, et al.
Bone Marrow Transplantation
|
July 15, 2003
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma
R Howe, I N M Micallef, D J Inwards, et al.
Bone Marrow Transplantation
|
July 5, 2016
Autologous stem cell transplant for multiple myeloma patients 70 years or older
E Muchtar, D Dingli, S Kumar, et al.
Leukemia
|
August 21, 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
T E Witzig, K M Laumann, M Q Lacy, et al.
Leukemia
|
July 12, 2012
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
J A Katzmann, R Clark, R A Kyle, et al.
Blood Cancer Journal
|
March 21, 2015
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
V Roy, A K Stewart, P L Bergsagel, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 154) with videos related to
Sort By:
Page
of 16
Leukemia
|
August 30, 2017
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
R Chakraborty, E Muchtar, S K Kumar, et al.
Bone Marrow Transplantation
|
October 12, 2010
Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention
S Sinha, D Gastineau, I Micallef, et al.
Blood
|
September 25, 2001
Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis
S R Hayman, R J Bailey, S M Jalal, et al.
Bone Marrow Transplantation
|
November 26, 2013
Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation
C O Freytes, D H Vesole, J LeRademacher, et al.
Bone Marrow Transplantation
|
September 4, 2003
Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
I M Ghobrial, A Dispenzieri, K L Bundy, et al.
Bone Marrow Transplantation
|
July 15, 2003
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma
R Howe, I N M Micallef, D J Inwards, et al.
Bone Marrow Transplantation
|
July 5, 2016
Autologous stem cell transplant for multiple myeloma patients 70 years or older
E Muchtar, D Dingli, S Kumar, et al.
Leukemia
|
August 21, 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
T E Witzig, K M Laumann, M Q Lacy, et al.
Leukemia
|
July 12, 2012
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
J A Katzmann, R Clark, R A Kyle, et al.
Blood Cancer Journal
|
March 21, 2015
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
V Roy, A K Stewart, P L Bergsagel, et al.
Page
of 16